Health Services Insights · مجلد 19 · 11786329261450733-11786329261450733
Introduction: The yearly observance of Ramadan, which includes prolonged daily fasting, presents a challenging scenario for patients with chronic illnesses, with existing studies presenting inconsistent findings on its metabolic implications. Objective: This study aimed to objectively measure the immediate and sustained impacts of Ramadan fasting on monthly mean Hemoglobin A1c (HbA1c), Systolic Blood Pressure (SBP), and Diastolic Blood Pressure (DBP) in a large, real-world cohort of Saudi Arabian patients with concomitant T2DM and HTN. Methods: A retrospective longitudinal study was carried out using electronic health record (EHR) data from a Saudi multi-facility healthcare system from December 2023 to May 2024. The analysis used a segmented regression for Interrupted Time Series (ITS) to estimate changes in outcomes, with Ramadan (March 2024) serving as the intervention point. Results: = .002), indicating a rebound impact. The reduction in SBP was not sustained, as it returned to pre-Ramadan levels in the months that followed. Conclusions: In this large Saudi cohort, Ramadan fasting was linked to transitory improvements in glycemic and blood pressure control. The ensuing rebound implies that, while fasting can be metabolically advantageous, the effects do not last without ongoing intervention. These results highlight the important necessity for rigorous post-Ramadan clinical follow-up to consolidate any gains made during the fasting period. These findings position Ramadan as a novel window for metabolic reset and a potential preventive opportunity against cardiorenal metabolic syndrome progression in high-risk populations.
Ramadan fastingtype 2 diabeteshypertensionglycemic control
Frontiers in Cellular and Infection Microbiology · مجلد 16
Correction on: Othman G, A. Badawy A, Hamed Al-Serwi R, El Sayed Zaki M, Tharwat Abou Elkhier N, Alkassaby NM and Saleh Ismail M (2026) Molecular epidemiology of carbapenemaseproducing gram-negative bacilli in diabetic foot infections: association with glycemic control. Front. Cell. Infect. Microbiol. 16:1847743. doi: 10.3389/fcimb.2026.1847743.Grant/funding/project number incorrect An incorrect number was provided for the Deanship of Scientific Research at Northern Border University, Arar, Saudi Arabia. The correct number is NBU-FFR-2026-52-03The original version of this article has been updated.
Frontiers in Cellular and Infection Microbiology · مجلد 16 · 1847743-1847743
Background Carbapenem-resistant Gram-negative bacilli are an increasing threat in diabetic foot ulcer (DFU) infections, limiting therapeutic options and worsening outcomes. However, data linking specific carbapenemase genes to clinical and metabolic factors remain limited. Objectives To isolate Gram-negative bacilli from deep tissue biopsies of DFUs, determine carbapenem susceptibility by minimum inhibitory concentration (MIC) testing, detect major carbapenemase genes by multiplex qPCR, and evaluate their association with glycemic control and Wagner grade. Methods This cross-sectional study included 150 patients with infected DFUs. Isolates recovered from tissue and other specimens were identified by standard microbiological methods, and carbapenem susceptibility was assessed by MIC testing. Multiplex qPCR was used to detect bla KPC, bla NDM, bla OXA-48, bla VIM, and bla IMP, and associations between resistance determinants and clinical variables were analyzed statistically. Results The mean patient age was 56.4 ± 9.8 years, with a male predominance (61.3%), and high-grade ulcers (Wagner III–V) were present in 54.7% of patients. Klebsiella pneumoniae predominated (60.0%), followed by Pseudomonas aeruginosa and Escherichia coli (each 14.7%). Resistance to meropenem and imipenem was high (77.3% and 75.3%, respectively), and carbapenemase production was detected in 84.0% of isolates. bla KPC (28.0%) and bla NDM (24.0%) were the most prevalent genes and were significantly associated with phenotypic carbapenemase production (P = 0.002 and P = 0.006, respectively). Carbapenemase producers showed significantly higher fasting glucose and HbA1c levels than non-producers (P < 0.001), with no significant association observed for Wagner grade (P = 0.570). Conclusions DFUs showed a high burden of carbapenemase-producing Gram-negative bacilli, driven mainly by bla KPC and bla NDM. Poor glycemic control was strongly associated with these resistant infections, underscoring the need for integrated metabolic management, molecular surveillance, and antimicrobial stewardship. These findings position glycemic control as a modifiable driver of antimicrobial resistance in DFUs.
Patient Preference and Adherence · مجلد Volume 20 · 1-21
Background: Medication adherence is critical for achieving optimal glycemic control and preventing diabetes-related complications. However, poor adherence remains a major barrier to effective diabetes management worldwide. Evidence regarding factors associated with medication adherence among adults with diabetes in Saudi Arabia remains limited. This study aimed to assess medication adherence among adults with diabetes and examine associations of sociodemographic, clinical, pharmacist-related, and digital health factors with adherence levels. Methods: A cross-sectional study was conducted among adults with type 1 or type 2 diabetes attending a specialized diabetes center in Jazan, Saudi Arabia, during February-March 2025. Participants were recruited using non-probability convenience sampling. Of 489 patients approached, 388 completed the questionnaire, yielding a response rate of 79.3%. Data were collected using a bilingual (Arabic/English) electronic questionnaire. Medication adherence was assessed using the 8-item Morisky Medication Adherence Scale (MMAS-8). Descriptive statistics, bivariate analyses, correlation analysis, and multinomial logistic regression were performed using IBM SPSS Statistics version 27. Results: Overall, 77.1% of participants demonstrated low medication adherence, while 16.5% and 6.4% demonstrated moderate and high adherence, respectively. In the adjusted multinomial logistic regression model, higher satisfaction with the current diabetes management plan was significantly associated with greater odds of moderate adherence (OR=1.650, 95% CI: 1.212-2.245, P=0.001) and high adherence (OR=2.038, 95% CI: 1.165-3.565, P=0.013) compared with low adherence. Insulin use was associated with moderate vs low adherence (OR=2.175, 95% CI: 1.008-4.692, P=0.048), but not with high adherence. Participants who did not use mobile applications or digital health tools had higher odds of high vs low adherence than those who used such tools (OR=2.685, 95% CI: 1.007-7.154, P=0.048). Age and comorbid conditions were not significantly associated with adherence level in the adjusted model. Frequency of pharmacist consultation was significant overall (P=0.001), although individual category comparisons did not demonstrate a consistent pattern across adherence levels. Multicollinearity diagnostics indicated no problematic collinearity (VIF=1.04-1.34; tolerance ≥0.75). Conclusion: Medication adherence was predominantly low among study participants. Higher satisfaction with diabetes management was consistently associated with greater adherence, while insulin use and digital health tool use showed category-specific associations. The unexpected association between digital-tool non-use and high adherence should be interpreted cautiously and does not establish a causal effect of digital technology on adherence. Further longitudinal and prospective studies are warranted to clarify these associations and determine how structured pharmacist engagement and personalized digital-health strategies can be optimally incorporated into patient-centered diabetes care.
OBJECTIVE: The aim of this study was to investigate the relationship between perceived stress and sleep quality with glycemic blood levels in T2DM patients in Riyadh. SUBJECT AND METHODS: This cross-sectional study evaluated a total of 309 patients diagnosed with type 2 diabetes mellitus in Riyadh, Saudi Arabia. The study comprised an initial validation and Arabic translation phase involving 160 participants, followed by an analytical phase focusing on 149 adult patients. To investigate the impact of psychosocial and metabolic factors on glycemic control (hemoglobin A1c [HbA1c]), data were collected using the Pittsburgh Sleep Quality Index (PSQI) and the Perceived Stress Scale (PSS-10), alongside clinical metrics such as body mass index (BMI) and dyslipidemia extracted from medical records. A multivariable linear regression model was utilized to identify independent factors associated with glycemic regulation within the local population. RESULTS: The multivariable regression model demonstrated robust explanatory power (adjusted R2 = 0.726, p < 0.001). Traditional risk factors, specifically elevated BMI (β = 0.448, p < 0.001) and dyslipidemia (β = 0.304, p < 0.001), were significantly associated with higher HbA1c levels. Notably, poor sleep quality emerged as a significant independent factor associated with elevated HbA1c (β = 0.261, p < 0.001), whereas perceived stress did not exhibit a significant correlation. Conversely, physical activity demonstrated a significant protective effect, correlating with lower HbA1c (β = -0.271, p < 0.001). CONCLUSION: Poor sleep quality, rather than perceived psychological stress, is a primary factor independently associated with hyperglycemia in this patient cohort. These findings suggest that standard diabetes care should integrate formal sleep assessments alongside patient care management.
type 2 diabetesperceived stresssleep qualityglycemic control
Frontiers in Pharmacology · مجلد 17 · 1822157-1822157
Background: The worldwide burden of metabolic dysfunction-associated steatotic liver disease (MASLD) is rising sharply, powered by high prevalence of obesity and its associated metabolic insults. Though urgent, definitive treatment is not yet available. Empagliflozin, a sodium glucose co-transporter inhibitor has been suggested in both human and animal studies to have diverse beneficial effects in MASLD by anti-inflammation and anti-oxidative stress effects, but many of the underlying mechanisms remain unexplained. The main aim of this systematic review and meta-analysis was to evaluate the effects of empagliflozin's in preclinical animal studies trying to view new horizons for future treatment of MASLD. Methods: we searched the related animal preclinical studies in databases including Scopus, Web of Science, Cochrane library, Wily online library and PubMed. The research team screened the literature and extracted data; any discrepancies were resolved by the research team leader through discussion. The quality of research methods was assessed by SYRCLE (systematic review center for laboratory animal experimentation) risk of bias tool. The meta-analysis was guided by the Cochrane Handbook; statistical analyses were conducted via RevMan 5.4 offline version and Comprehensive Met analysis V3 software. Results: Our meta-analysis included 17 studies, involving 584 animals. In comparison with the model group, empagliflozin significantly reduced steatosis markers including hepatic burden of lipids, including triglycerides and cholesterol, NAFLD Activity Score (NAS) and total serum cholesterol (TC). It also significantly reduced hepatic fibrosis markers including fibrosis grade, transforming growth factor-β (TGF-β) and collagen type I alpha 1 chain) COL1A1). Beyond its anti-steatofibrotic effects, empagliflozin significantly downregulated hepatic expression of inflammatory and oxidative markers including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) and malondialdehyde (MDA). Moreover, empagliflozin significantly improved glycemic indices including Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), serum insulin, and fasting blood sugar (FBS). Conclusion: Empagliflozin significantly protected the liver against steatosis and fibrosis by mitigating hepatic inflammation, oxidative stress and insulin resistance.
Journal of the Egyptian Ophthalmological Society · مجلد 119 (2) · 165-170
Background Diabetic retinopathy (DR) is a leading cause of visual impairment and blindness worldwide. It develops as a complication of diabetes mellitus and often progresses without noticeable symptoms until vision is severely compromised. Early detection through regular screening is crucial to prevent vision loss, as timely intervention can slow disease progression. Enhancing public awareness about DR and the importance of routine ophthalmic examinations is essential for reducing its impact. Objective This study aimed to assess the level of awareness of DR among the Saudi population. Patients and methods A cross-sectional study was conducted using an online questionnaire distributed across various regions of Saudi Arabia after obtaining Institutional Review Board (IRB) approval. A total of 1000 Saudi participants aged 18 years and above were recruited using a snowball sampling method. Results Among the participants, 65.6% were females, with the largest age group between 18 and 29 years (55.5%). The central region provided the highest response rate (25%). The study revealed a high level of awareness, with 91.6% recognizing that diabetes affects the eyes and 83.5% acknowledging the need for regular screening even without symptoms. Additionally, 93.2% understood that good glycemic control can prevent DR, while 81.6% knew that DR is treatable. Furthermore, 85% were aware that the duration of diabetes influences DR development, and 83% recognized hypertension as a contributing factor. Conclusion The Saudi population demonstrates commendable awareness of DR. Continuous public health initiatives and educational campaigns are necessary to sustain and further enhance awareness, encouraging preventive practices and early detection.
AIM: To evaluate the efficacy and outcomes of integrative technologies employed in nursing-led interventions for the management of diabetes. BACKGROUND: With the global rise in diabetes prevalence, there is growing interest in digital health solutions to improve disease self-management. Nurses are increasingly leveraging technologies, such as mobile applications, wearable devices, and telehealth platforms, to support individuals with diabetes. However, the effectiveness and implementation outcomes of such nursing-led digital interventions remain variably reported in the literature. METHODS: A systematic review was conducted following PRISMA 2020 guidelines. Comprehensive five database searches (PubMed, CINAHL, Scopus, Web of Science, and Embase) identified randomized controlled trials (RCTs) from 2013 to 2024. Studies were included if they involved nurse-led interventions incorporating digital technologies for diabetes management. Data were synthesized using narrative and thematic analysis. Risk of bias was assessed using the RoB 2 tool. RESULTS: Thirteen RCTs involving diverse technologies demonstrated improvements in glycemic control (HbA1c reduction), self-management behaviors, and quality of life. Interventions incorporating personalized coaching, regular follow-up, and patient-centered feedback were particularly effective. Most studies were rated as low risk of bias, though some showed concerns regarding reporting practices and intervention fidelity. CONCLUSION: Nursing-led digital health interventions can significantly enhance diabetes care outcomes. Their success is contingent upon sustained patient engagement, nurse training, and organizational support. Broader implementation requires addressing digital literacy and system-level integration challenges. IMPLICATIONS FOR PRACTICE: Nurse-led technologies should be embedded in care models to support scalable, personalized, and effective diabetes self-management across diverse settings. CLINICAL TRIAL NUMBER: Not applicable.
diabetes managementnurse-led interventiondigital health technologiesmobile health apps
Frontiers in Pharmacology · مجلد 16 · 1507009-1507009
Background: Metformin, hypoglycemic medication, is recognized for its diverse properties and its capacity to influence the inflammatory pathways. Medications with anti-inflammatory and anti-oxidative characteristics have been demonstrated to be able to elicit and sustain remission in ulcerative colitis (UC), chronic inflammatory disorder of the bowel. Studies in both preclinical and clinical settings have looked into the several metabolic pathways via which metformin protects against UC. Aim: To assess efficacy of metformin as adjunctive therapy in patients with mild to moderate UC. Methods: This clinical research was double-blinded, randomized, controlled, and involved 60 patients with mild to moderate UC. The participants were randomly assigned to one of two groups (n = 30). The control group was given 1 g of mesalamine three times a day (t.i.d.) for a period of 6 months (mesalamine group). The metformin group was given 500 mg of metformin twice daily and 1 g of mesalamine t. i.d. For a period of 6 months. Patients with UC were assessed by a gastroenterologist using the disease activity index (DAI) both at the beginning of treatment and 6 months thereafter. To evaluate the drug's biological efficacy, measurements of fecal calprotectin, serum C-reactive protein (CRP), interleukin 10 (IL-10), and nitric oxide (NO) were taken both before and after treatment. Study outcomes: Decrease in DAI and change in the level of measured serum and fecal markers. Results: = 0.04) when compared to the mesalamine group. There was a significant direct correlation between DAI and calprotectin (p < 0.0001, r = 0.551), and between DAI and CRP (p < 0.0001, r = 0.794). There was a significant negative correlation between DAI and IL-10 (p = 0.0003, r = 0.371). Conclusion: Metformin may be an effective adjunct drug in management of patients with mild to moderate UC by decreasing DAI and other inflammatory markers that were involved in the pathogenesis of UC. Clinical Trial Registration: identifier NCT05553704.
Libyan Journal of Medicine · مجلد 20 (1) · 2585617-2585617
Metabolically dysfunction-associated steatotic liver disease (MASLD) has emerged as the leading chronic liver disease worldwide, driven primarily by metabolic derangement. The current investigation proposes to elucidate the hepatoprotective mechanisms of telmisartan (TEL) in MASLD. Twenty-four male Wistar rats were allocated to four groups (Control, MASLD, TEL-treated, and MASLD/TEL). Lipid profiles, glycemic markers, liver enzymes, and hepatic markers of oxidative stress (malondialdehyde (MDA), glutathione (GSH), superoxide dismutase (SOD), and catalase) were measured. MASLD-associated genes retrieved from GeneCards® were mapped to Rattus norvegicus ortholog genes using the gprofiler2 R package. Kyoto Encyclopedia of Genes and Genomes (KEGG) and Reactome enrichment analyses were subsequently performed using the clusterProfiler R package. Hepatic inflammatory cytokines (TNF-β, IL-6, and NF-κB), mitochondrial respiratory enzymes (Complexes I–IV), and the gene expression of Nrf2, HO-1, MMP-9, and TIMP-1 were evaluated using spectrophotometric assays for mitochondrial respiratory enzymes. Histological assessment was done using Hematoxylin and Eosin (H&E) staining, Masson's trichrome, and TGF-β immunostaining. TEL ameliorates MASLD-associated disturbances in the serum ALT level and lipid profile. It significantly reduces the levels of oxidative stress markers. KEGG and Reactome enrichment highlighted pathways involved in lipid metabolism, insulin resistance, and inflammation, with the peroxisome proliferator–activated receptor (PPAR) and AMP-activated protein kinase (AMPK) signaling pathways being the most enriched. TEL treatment increased the hepatic expression of Nrf2, HO-1, and TIMP−1 while decreasing the expression of MMP-9. The levels of the proinflammatory cytokines TNF-α and IL-6 decreased. The activities of mitochondrial enzymes (citrate synthase and complex I) improved. MASLD induced marked hepatic fibrosis, which was markedly improved following TEL treatment. TEL has notable hepatoprotective properties in MASLD by enhancing metabolic parameters, decreasing oxidative stress, and moderating inflammatory reactions.
Nonalcoholic fatty liver disease (NAFLD) is a common comorbidity in individuals with type 2 diabetes mellitus (T2DM), contributing to increased liver-related complications and cardiovascular risk. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as potential treatments offering benefits for both metabolic and liver-related outcomes. This systematic review evaluated the efficacy of SGLT2 inhibitors in improving hepatic steatosis, liver enzymes, glycemic control, and liver histology in patients with T2DM and NAFLD. The review was conducted using a structured methodology, including systematic database searches and risk of bias assessments. Included randomized controlled trials (RCTs) investigated various SGLT2 inhibitors, such as dapagliflozin, empagliflozin, ertugliflozin, and ipragliflozin. Most studies showed significant reductions in liver fat content, improvements in serum liver enzymes (alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT)), and favorable effects on blood pressure, triglycerides, and body composition. Glycemic control markers, including glycated hemoglobin (HbA1c), fasting glucose, and insulin resistance indices, also improved. One biopsy-based study demonstrated histological improvements, including reduced fibrosis and resolution of nonalcoholic steatohepatitis (NASH). No serious adverse events were reported. These findings suggest SGLT2 inhibitors may offer dual benefits for managing both diabetes and fatty liver disease. Further long-term studies focusing on liver histology as a primary endpoint are needed to confirm these effects.
Journal of Anatomical Society of India · مجلد 74 (2) · 92-103
Background: Diabetes mellitus poses a significant health challenge worldwide. Oxidative stress, altered lipid profile, and inflammation are linked to diabetic complications. Objective: This work aimed to assess the effects of taurine (TAU) in alloxan (ALX)-induced diabetes in rats, evaluating its antihyperglycemic, antidyslipidemic, antioxidant, and anti-inflammatory effects. In addition, evaluating the effect of TAU on hepatic, renal, and cardiac complications. Materials and Methods: Fifty rats were divided into four groups, control, TAU, ALX, and ALX + TAU. At the end of the experiment, blood and tissue were collected and subjected to serum glucose, insulin, lipid profile, liver enzyme, creatinine, urea detection, oxidative-antioxidant parameters evaluation, inflammatory, anti-inflammatory cytokines detection, and histological evaluation. Results: Experimental results demonstrated that TAU effectively mitigated hyperglycemia, dyslipidemia, oxidative stress, and inflammatory conditions induced by ALX. TAU treatment improved serum glucose and insulin levels, restored lipid profiles, enhanced antioxidant enzyme activities, and reduced lipid peroxidation. In addition, TAU ameliorated hepatic and renal function alterations preserved histological architecture in the pancreas, liver, kidney, and heart tissues, and modulated inflammatory responses by diminishing the inflammatory mediators interleukin-6 (IL-6) and tumor necrosis factor-α while augmenting the anti-inflammatory mediator IL-10. Conclusions: TAU exerts a therapeutic effect on ALX-induced hepatic, renal, and cardiac diabetic complications by lowering blood glucose levels, augmenting insulin secretion, ameliorating dyslipidemia, preserving the oxidative-redox balance, and boosting antioxidant activity. TAU has also an anti-inflammatory impact.
Self-monitoring of blood glucose (SMBG) is a widely used strategy in diabetes management, allowing patients to track their glucose levels and make informed decisions regarding diet, medication, and lifestyle adjustments. The effectiveness of SMBG remains debated. Structured SMBG, which involves systematic monitoring with clear guidance, has been suggested to provide greater benefits compared to unstructured SMBG. We aimed to evaluate the effectiveness of SMBG in improving glycemic control among diabetic patients. A systematic search was conducted in PubMed, the Cochrane Library, and Google Scholar. Studies were included if they examined SMBG interventions and reported glycated hemoglobin (HbA1c) as an outcome. Randomized controlled trials (RCTs) and observational studies were assessed for quality using the Cochrane Risk of Bias Tool and the Newcastle-Ottawa Scale. Meta-analysis was performed using Review Manager (RevMan, The Cochrane Collaboration, Copenhagen, Denmark) to calculate mean differences (MD) and 95% confidence intervals (CI). The comprehensive database search yielded 7,667 records, of which 22 articles were selected for review and analysis. The meta-analysis of 22 studies showed that SMBG significantly reduced HbA1c levels compared to no SMBG (MD = -0.32%, 95% CI: -0.44% to -0.20%). Structured SMBG resulted in a greater reduction (MD = -0.25%, 95% CI: -0.41% to -0.09%) compared to unstructured SMBG. In summary, we showed that SMBG is effective in lowering HbA1c, particularly when structured protocols are followed. Healthcare providers should promote structured SMBG, along with patient education, to enhance adherence and optimize glycemic control. Further long-term studies are necessary to evaluate long-term benefits.
self-monitoring of blood glucoseglycemic controldiabetes mellitusHbA1c
Frontiers in Pharmacology · مجلد 15 · 1364110-1364110
Background: Pancreatitis is characterized by inflammation of the pancreas and significantly affects quality of life. Less than 5% of pancreatitis cases are drug-induced, but recent evidence suggests a substantial risk associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs). The aim of this study was to compare the risk of developing pancreatitis between those using GLP-1 RAs and those using sodium-glucose transport protein 2 (SGLT2) inhibitors and dipeptidyl peptidase 4 (DPP-4) inhibitors. Methods: This study was done using the FDA Adverse Event Reporting System (FAERS) database from 2019 to 2021. This database contains information from diverse submissions from healthcare providers, patients, and manufacturers. To ensure fairness and accuracy, the risk of pancreatitis associated with other hypoglycemic agents (SGLT2 inhibitors and DPP-4 inhibitors) was also investigated. Traditional and Bayesian statistical analysis methods were used to identify disproportionate statistics and included the reporting odds ratio (ROR), proportional reporting ratio (PRR), empirical Bayes geometric mean (EBGM), and information component (IC). A drug–adverse-event combination that met the criteria of all four indices was deemed a signal. Results: The analysis of 2,313 pancreatitis reports linked to hypoglycemic agents revealed a predominant association with GLP-1 RA (70.2%) compared to DPP-4 inhibitors (15%) and SGLT2 (14.7%). Most of these reports involved female patients (50.4%), and the highest incidence occurred in those over 50 years old (38.4%). Additionally, 17.7% of the reports were associated with serious events. The ROR was significant for the risk of pancreatitis when using DPP-4 (13.2, 95% confidence interval (CI) 11.84-14.70), while the ROR for GLP-1 was 9.65 (95% CI 9.17-10.16). The EBGM was highest with DPP-4 (12.25), followed by GLP-1 (8.64), while IC was highest with DPP-4 inhibitors (3.61). Liraglutide had the greatest association with pancreatitis among the GLP-1 RAs (ROR: 6.83, 95% CI 6.60-7.07). Conclusion: The findings show that pancreatitis has a strong link with DPP-4 inhibitors and GPL1 agonists, which pose a greater risk. Among the GLP-1 agonist medications, liraglutide has been found to have an association with pancreatitis.
International Journal of Pharmaceutics X · مجلد 7 · 100232-100232
Diabetes mellitus (DM) is the most prevalent cause of diabetic retinopathy (DRP). DRP has been recognized for a long time as a microvascular disease. Many drugs were used to treat DRP, including vildagliptin (VLD). In addition to its hypoglycemic effect, VLD minimizes ocular inflammation and improves retinal blood flow for individuals with type 2 diabetes mellitus. Nevertheless, VLD can cause upper respiratory tract infections, diarrhea, nausea, hypoglycemia, and poor tolerability when taken orally regularly due to its high water solubility and permeability. Effective ocular administration of VLD is achieved using solid lipid nanoparticles (SLNPs), which improve corneal absorption, prolonged retention, and extended drug release. Ocuserts (OCUs) are sterile, long-acting ocular dosage forms that diminish the need for frequent dosing while improving residence time and stability. Therefore, this study intends to develop VLD solid lipid nanoparticle OCUs (VLD-SLNPs-OCUs) to circumvent the issues commonly associated with VLD. SLNPs were prepared using the double-emulsion/melt dispersion technique. The optimal formula has been implemented in OCUs. Optimization and development of VLD-SLNPs-OCUs were performed using a Box-Behnken Design (BBD). VLD-SLNPs-OCUs loading efficiency was 95.28 ± 2.87%, and differential scanning calorimetry data (DSC) showed the full transformation of VLD to an amorphous state and the excellent distribution in the prepared OCUs matrices. The in vivo release of VLD from the optimized OCUs after 24 h was 35.12 ± 2.47%, consistent with in vitro drug release data of 36.89 ± 3.11. The optimized OCUs are safe to use in the eye, as shown by the ocular irritation test. VLD-SLNPs-OCUs provide extended VLD release, an advantageous alternative to conventional oral dose forms, resulting in fewer systemic adverse effects and less variation in plasma drug levels. VLD-SLNPs-OCUs might benefit retinal microvascular blood flow beyond blood glucose control and may be considered a promising approach to treating diabetic retinopathy.
vildagliptinsolid lipid nanoparticlesOcusertocular drug delivery